Aging Frailty

Mesenchymal stem cells (MSCs) are being studied in aging frailty to examine whether their biological effects might support resilience and reduce vulnerability in elderly. 

Frailty is a clinical condition characterized by reduced strength, lower endurance, and decreased physiological reserve, leading to higher risk of falls, hospitalization, and mortality. It represents a major challenge in aging populations. 

Research into MSCs in frailty is at an exploratory stage but contributes to scientific knowledge on regenerative medicine and healthy aging. 

Clinical Trials

Frailty syndrome: an overview — Xujiao Chen, et al.


 

The frailty syndrome: definition and natural history — Qian-Li Xue, et al.


 

Frailty as a predictor of hospitalisation among community-dwelling older people: a systematic review and meta-analysis — Gotaro Kojima, et al.


 

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty — Luigi Ferrucci, et al.


 

Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases — Claudio Franceschi, et al.


 

Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial — Bryon A Tompkins, et al.


 

Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty — Samuel Golpanian, et al.